Novel centrosome protein, TCC52, is a cancer-testis antigen

Cancer Sci. 2008 Nov;99(11):2274-9. doi: 10.1111/j.1349-7006.2008.00937.x. Epub 2008 Oct 14.


A novel centrosome protein, TCC52, was identified as a cancer-testis (CT) antigen. The TCC52 gene was tissue-restricted in normal tissues but highly expressed in lung cancer tissues and some cancer cell lines. Immunoglobulin G antibody specific to TCC52 was detected in serum samples from patients with prostate cancer (59.4%, 69/116), cholangiocarcinoma (17.6%, 6/34), laryngeal cancer (8%, 8/100) and lung cancer (5.6%, 4/71) in patients, rather than from healthy donors. Based on its restricted expression pattern and immunogenicity in some types of tumor, TCC52, as a novel CT antigen, would be a promising candidate for cancer immunotherapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antigens, Neoplasm / genetics
  • Antigens, Neoplasm / immunology*
  • Antigens, Neoplasm / metabolism*
  • Cell Line, Tumor
  • Centrosome / immunology
  • Centrosome / metabolism*
  • Gene Expression Profiling
  • Humans
  • Immunohistochemistry
  • Male
  • Neoplasms / immunology*
  • Neoplasms / metabolism
  • Testis / immunology*
  • Testis / metabolism


  • Antigens, Neoplasm
  • DCAF12 protein, human